Global Leader in Oral Delivery of Therapeutic Proteins

We are a clinical stage, global company, focused on high unmet clinical needs where oral delivery of a protein therapy can significantly improve the standard of care


Entera is Daring Courageous Fierce

We are developing first-in-class, daily tablet protein and peptide replacement therapies, designed for patients to live healthier and injection-free, as they manage their chronic diseases. Our goal is for our small, oral protein tablets to change treatment outcomes for patients globally.

Therapeutic Areas


Osteoporosis is a disease characterized by low bone mass and structural deterioration of bone tissue, which leads to greater fragility and an increase in fracture risk.

Hypoparathyroidism is a rare condition in which the parathyroid glands fail to produce sufficient amounts of parathyroid hormone or the parathyroid hormone produced lacks biologic activity.

Our 2018 license agreement with Amgen, we are developing oral formulations of novel therapeutic protein candidates.


Press Releases

Entera Bio Announces FDA’s Acceptance of a Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets, as the First Oral Osteoanabolic Treatment of Post-Menopausal Osteoporosis

Entera Bio Presents Dose Proportional Absorption and Correlation to BMD Clinical Response Data from its Phase 2 Study of EB613 in Post-Menopausal Osteoporosis Patients at the ASBMR 2022 Annual Meeting


Key Opinion Leader Webinar on the Treatment Landscape for Osteoporosis and EB613’s Potential Impact

Thank You

Message Sent!

We will get back to you soon